Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy.
about
The EMPA-REG outcome study: critical appraisal and potential clinical implicationsThe metabolic vascular syndrome - guide to an individualized treatmentThe Evolution of the Stem Cell Theory for Heart FailureEfficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysisAntidiabetic treatment with gliptins: focus on cardiovascular effects and outcomesIncreased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic KidneysAddition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysisInsulin Signaling and Heart Failure.Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.The regulatory role of DPP4 in atherosclerotic disease.Unsticking the Broken Diabetic Heart: O-GlcNAcylation and Calcium Sensitivity.Cardiovascular effects of the incretin-based therapy: the good, the bad, or the ugly?DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety.cAMP-dependent Protein Kinase (PKA) Signaling Is Impaired in the Diabetic HeartDiabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities.Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical ConsiderationsAntihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease.Associations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus.Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes.Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial.Increased mortality risk in diabetic patients discharged from hospital with insulin therapy after an acute myocardial infarction: Data from the FAST-MI 2005 registry.Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat.Saxagliptin for the treatment of diabetes - a focus on safety.Green tea EGCG enhances cardiac function restoration through expression of survival signaling in DM rats with autologous adipose tissue-derived stem cell.Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know.How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes.Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.Reframing the association and significance of co-morbidities in heart failure.Glycaemic control and cardiovascular disease: is there a light at the end of the tunnel?Cardiovascular safety of therapies for type 2 diabetes.Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet.The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus.Novel approaches to the treatment of hyperglycaemia in type 2 diabetes mellitus.Inhibition of dipeptidyl peptidase-4 ameliorates cardiac ischemia and systolic dysfunction by up-regulating the FGF-2/EGR-1 pathway.Psoralea corylifolia L. Seed Extract Attenuates Diabetic Nephropathy by Inhibiting Renal Fibrosis and Apoptosis in Streptozotocin-Induced Diabetic Mice.Hsp20-Mediated Activation of Exosome Biogenesis in Cardiomyocytes Improves Cardiac Function and Angiogenesis in Diabetic Mice.PDE5 Inhibitor Tadalafil and Hydroxychloroquine Cotreatment Provides Synergistic Protection against Type 2 Diabetes and Myocardial Infarction in Mice.
P2860
Q26748742-A45448C8-F346-4E3E-8E61-F20EAAF03BE5Q26767142-6CDE7E45-5BEF-47E9-A51C-4B1F7D52AAC9Q26769042-8127F15C-4248-44C8-A67B-F9EB35B5F307Q26773030-638C91D3-C3AF-4387-86B6-1C35F863E0C3Q26785454-3AC288D5-2180-48F1-AA3C-677D7C825C54Q28072939-4DD1F22F-4B35-4467-AE89-2F491F61DF8EQ28275281-5FB3D24A-523B-4E09-8AB6-D6CD3CC261E8Q30377910-9CB129C9-0B50-4DC1-B849-84324BF9B05FQ30846870-C563FEF3-5E5D-4B05-A381-CBA7DF91EEE6Q33660548-C10F3E6B-0E9B-4B60-A914-CB47A3A54B3CQ33805518-2116B799-CFFE-4062-A24D-93CB212247F4Q36104623-20B36AC8-F0BF-42BB-B3C8-C9A963096818Q36232737-C121B9E9-D13B-43D6-9E79-4B229ECDCD2DQ36338382-3A32A8AC-9217-422C-BB95-D9935504F74AQ36444031-F9945BAB-6C27-4A0E-AAFD-B788C50BD3ADQ36479405-121102A5-BF31-4B9F-AEEC-B4941069F30CQ37011769-A243A8A0-F0F9-4CA9-874E-4A51BFA59FBFQ37103963-D89B8B06-7BDA-49AB-B343-14D8E0AFB276Q37337371-A184534B-E39D-43EF-9124-0447DC644B08Q37594479-A3AB8835-9EB2-4190-A497-359F3EE11282Q38374511-BFDE257E-B250-43F2-9141-B3C96B57BC9BQ38686913-A5C7271C-AEAF-4E9F-BB83-68CC6F85D73FQ38752958-6E5D1D5A-E5A4-46AC-A1C6-8E1B1718D7E2Q38753500-76B5D73B-49A3-4E11-9B31-A92FBB9C8744Q38762789-F761A1F1-2275-4908-B23A-0FD4DE15EB99Q38787756-04FB3F51-1DAF-4283-B03A-F700D3C9CB4DQ38797551-10F2BE4B-FBDA-45A6-B037-53FA3ADC1E17Q38815498-0F606444-EBE1-48F8-BAA4-ACB16ACB2D2FQ38836416-AFC220E7-A47C-4F33-93FC-00BBCE41596AQ38881287-A9E2865E-D84F-49DB-ACFA-7B081A7D911BQ38926914-5CDEAC97-7E0E-447B-8374-82566A41AE39Q38960547-F2FC212A-E00F-4674-9B39-C80F438411FAQ38960765-A948AC9A-DEEE-4B79-8D33-2F5BAF3C9CC8Q39000136-21032FE5-2340-4113-8497-5E828B2D9CC9Q39256900-89D451F6-DEEA-4B7E-B1D6-A81ED898E869Q40758518-FB2BB206-A4FC-4DF9-AE6E-F820B3CF39D5Q41237048-43138857-A0FA-4EF9-B269-4B6AC9F413B4Q41583942-6227C110-F88B-49AD-AB23-25C833808C66Q41640134-1B0215CE-5422-4E36-9F0D-B58360FC3FD0Q41913523-714D2FDC-0970-40E3-AFC0-B2D2328430E0
P2860
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy.
@en
type
label
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy.
@en
prefLabel
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy.
@en
P1433
P1476
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy.
@en
P2093
Richard E Gilbert
P304
P356
10.1016/S0140-6736(14)61402-1
P407
P50
P577
2015-05-01T00:00:00Z